The clinical features of anti-NF155 antibody-positive CIDP include younger age at onset, predominant distal limb weakness, high-amplitude and low-frequency tremors, ataxia with cerebellar features, and a higher prevalence of poor response to IVIG when compared with seronegative patients (Querol et al., 2014; Kadoya et al., 2016). The gene discussed is PMP22; the disease is Ataxia.